31
Whole Lung Lavage (WLL)/Inhaled Granulocyte-macrophage Colony-stimulating Factor (GM-CSF) in Autoimmune Pulmonary Alveolar Proteinosis (PAP)
Condition(s):Pulmonary Alveolar ProteinosisLast Updated:July 28, 2009Unknown status
Leukine: 749 Clinical Trials, Page 4 of 75
Hide Studies Not Open or Pending
32
Efficacy Study of Sargramostim in the Retreatment of Patients Who Have Crohn’s Disease Who Have Previously Responded to Treatment With Sargramostim
Condition(s):Crohn DiseaseLast Updated:December 4, 2013Terminated
33
Dinutuximab in Combination With Sargramostim in Treating Patients With Recurrent Osteosarcoma
Condition(s):Metastatic Malignant Neoplasm in the Lung; Metastatic Osteosarcoma; Recurrent OsteosarcomaLast Updated:January 3, 2023Active, not recruiting
34
GM-CSF to Decrease ICU Acquired Infections
Condition(s):Septic Shock; Severe SepsisLast Updated:November 1, 2019Completed
35
Rituximab Plus Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia
Condition(s):LeukemiaLast Updated:September 19, 2018Completed
36
Docetaxel and Vinorelbine Plus Sargramostim in Metastatic Malignant Melanoma
Condition(s):Metastatic MelanomaLast Updated:May 3, 2018Completed
37
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
Condition(s):Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Lymphoma, Non-Hodgkin; Hodgkin Disease; Leukemia, Lymphocytic, Chronic, B-Cell; Multiple MyelomaLast Updated:June 5, 2017Completed
38
PANVAC-V and PANVAC-F Vaccines Plus Sargramostim to Treat Advanced Cancer
Condition(s):Adenocarcinoma; Colorectal Cancer; Ovarian Cancer; Breast CancerLast Updated:April 16, 2019Completed
39
Phase II Study of Azacitidine and Sargramostim as Maintenance Treatment for Poor-Risk AML or MDS
Condition(s):Acute Myeloid Leukemia; Myelodysplastic SyndromeLast Updated:October 18, 2022Completed
40
FCR Plus Sargramostim (GM-CSF) as Frontline Therapy for Symptomatic Chronic Lymphocytic Leukemia
Condition(s):Chronic Lymphocytic LeukemiaLast Updated:January 14, 2016Completed